Fluenz Tetra (influenza vaccine (live attenuated, nasal))
- Region
- 🇪🇺 EU
- Active substance
- influenza vaccine (live attenuated, nasal)
- Company
- AstraZeneca AB
- Status
- Withdrawn
- Therapeutic area
- Influenza, Human
- CHMP opinion
- Thu 19 Sep 2013
- EU approval
- Wed 04 Dec 2013
- Application
- EMEA/H/C/002617
- ATC
- J07BB03
- Official record
- www.ema.europa.eu
Indication
Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. The use of Fluenz Tetra should be based on official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
Follow Fluenz Tetra
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.